Dong Yi-Wei, Shi Yan-Qiang, He Li-Wen, Su Pei-Zhu
The Second Clinical Medical School, Southern Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
Department of Gastroenterology, Zhujiang Hospital, Southern Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
Onco Targets Ther. 2016 May 25;9:3127-34. doi: 10.2147/OTT.S103031. eCollection 2016.
Inflammatory responses play decisive roles in tumor development, immune surveillance, and responses to therapy. High neutrophil-to-lymphocyte ratio (NLR), as an inflammation index, has been reported to be a predictor for poor prognosis of various cancers. The purpose of this meta-analysis was to evaluate the prognostic value of NLR in patients with rectal cancer.
A comprehensive search of the literature was conducted through PubMed and EMBASE. Pooled hazard ratio (HR) with 95% confidence interval (CI) was used to evaluate the association between NLR and three outcomes: overall survival, disease-free survival, and recurrence-free survival.
Seven cohorts involving 959 patients were included in this meta-analysis. Our pooled results demonstrated that elevated NLR was associated with poor overall survival (HR: 13.41, 95% CI: 4.90-36.72), disease-free survival (HR: 4.37, 95% CI: 2.33-8.19), and recurrence-free survival (HR: 3.64, 95% CI: 1.88-7.05).
An elevated NLR is a valuable and easily available prognostic marker for rectal cancer. It is associated with unfavorable overall survival, disease-free survival, and recurrence-free survival. NLR could be a useful candidate factor for making treatment decisions for individual patients with rectal cancer.
炎症反应在肿瘤发展、免疫监视及治疗反应中起决定性作用。据报道,高中性粒细胞与淋巴细胞比值(NLR)作为一种炎症指标,是多种癌症预后不良的预测指标。本荟萃分析的目的是评估NLR在直肠癌患者中的预后价值。
通过PubMed和EMBASE对文献进行全面检索。采用合并风险比(HR)及95%置信区间(CI)评估NLR与总生存、无病生存和无复发生存三种结局之间的关联。
本荟萃分析纳入了7个队列,共959例患者。我们的合并结果表明,NLR升高与总生存不良(HR:13.41,95%CI:4.90 - 36.72)、无病生存不良(HR:4.37,95%CI:2.33 - 8.19)及无复发生存不良(HR:3.64,95%CI:1.88 - 7.05)相关。
NLR升高是直肠癌一个有价值且易于获得的预后标志物。它与不良的总生存、无病生存和无复发生存相关。NLR可能是为直肠癌个体患者制定治疗决策的一个有用候选因素。